Physician profile
April Tate
NPI 1801446190
$16,016.24
in general payments reported to CMS, 2019-2025
25 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,365 · 2022: $2,255 · 2023: $7,896 · 2024: $3,033 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,200 · Food and Beverage: $2,404 · Travel and Lodging: $780 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,200.00 |
| Food and Beverage | $2,403.87 |
| Travel and Lodging | $780.35 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12,543.49 | 2021-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $1,120.85 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $682.48 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $495.34 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.53 | 2022-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $115.35 | 2021 | |
| Glaxosmithkline, LLC. | $105.23 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $97.96 | 2021-2023 | Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.00 | 2021-2023 | Jardiance |
| Emd Serono, INC. | $70.53 | 2023 | Mavenclad |
| Merck Sharp & Dohme LLC | $61.19 | 2021-2024 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $59.01 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $54.11 | 2024-2025 | Voquezna |
| Abbvie INC. | $51.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.21 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.58 | 2021 | |
| Pfizer INC. | $40.72 | 2024-2025 | |
| Abbott Laboratories | $38.45 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $36.40 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $23.28 | 2024 | Nexletol |
| Smith+Nephew, INC. | $21.84 | 2025 | Collagenase Santyl |
| Exact Sciences Corporation | $20.89 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $17.20 | 2021 | |
| Philips North America LLC | $15.08 | 2024 | (Ak6) Vest Therapy |
| Dexcom, INC. | $12.69 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.